ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous...
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
About this item
Full title
Author / Creator
Publisher
Basingstoke: Nature Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
Basingstoke: Nature Publishing Group
Subjects
More information
Scope and Contents
Contents
The deregulated kinase activity of p210-BCR/ABL oncoproteins, hallmark of chronic myelogenous leukaemia (CML), induces and sustains the leukaemic phenotype, and contributes to disease progression. Imatinib mesylate, a BCR/ABL kinase inhibitor, is effective in most of chronic phase CML patients. However, a significant percentage of CML patients deve...
Alternative Titles
Full title
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2360538
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2360538
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/sj.bjc.6603317
